the impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous pregnancy-induced diabetes

Conditions: Gestational Diabetes Mellitus

Summary: it is well-known that women with previous gestational diabetes mellitus are in risk of developing type 2 diabetes later in life; approximately half of the women develop overt type 2 diabetes within the first 10 years after pregnancy. knowing this, we want to examine the effect of the type 2 diabetes medicine, liraglutide (victoza), in women with previous gestational diabetes with the aim of reducing the risk of developing type 2 diabetes.


Eligibility criteria:
inclusion criteria for women with previous gdm: * informed oral and written consent * previous diagnosis of gdm according to current danish guidelines (mainly pg concentrationa t 120 min after 75 g ogtt ≥ 9.0 mm) during pregnancy within the last 5 years * age \>18 years * 25 kg/m2 \< bmi \< 45 kg/m2 * ngt, ifg and or igt * safe contraception and negative pregnancy test exclusion criteria for women with previous gdm: * patients with diabetes * hba1c ≥6.5% * patients with previous pancreatitis or previous neoplasia * pregnant or breast feeding women * anaemia (haemoglobin \<7 mm) * women planning to become pregnant within the next 5 years * women using other contraception than intrauterine device (iud) or oral contraceptives. women who do not use safe contraception will be offered application of an iud. * women treated with statins, corticosteroids or other hormone therapy (except estrogens and gestagens) * ongoing abuse of alcohol or narcotics * impaired hepatic function (liver transaminases \>3 times upper normal limit) * impaired renal function (se-creatinine \>120 μm and/or albuminuria) * uncontrolled hypertension (systolic blood pressure \>180 mmhg, diastolic blood pressure \>100 mmhg) * any condition that the investigator feels would interfere with trial participation * receiving any investigational drug within the last 3 months inclusion criteria for women without previous gdm: * informed oral and written consent * age \>18 years * 25 kg/m2 \< bmi \< 45 kg/m2 * ngt * safe contraception and negative pregnancy test * pregnancy within the last ten years without gdm exclusion criteria for women without previous gdm : * pregnant or breast feeding women * anaemia (haemoglobin \<7 mm) inclusion criteria for women without previous gdm and without nafld: * informed oral and written consent * age \>18 years * 25 kg/m2 \< bmi \< 45 kg/m2 * ngt * at least one pregnancy witin the last ten years without gdm exclusion criteria for women without previous gdm and without nafld: * pregnant or breast feeding women * anaemia (haemoglobin \<7 mm) * steatosis as assessed by ultrasound scanning * recieving any investigational drug within the last 3 months * any condition that the investigator feels would interfere with the trial participation inclusion criteria for women with biopsi-verified nafld: * informed oral and written consent * women with known nafld or nash * age \>18 years * 25 kg/m2 \< bmi \< 45 kg/m2 * ngt * at least one prior pregnancy exclusion criteria for women with biopsi-verified nafld: * women with established cirrhosis * pregnant or breast feedning women * anaemia (haemoglobin \<7 mm) * women treated with statins, corticosteroids or other hormone therapy ( except oestrogens and gestagens) * ongoing abuse of alcohol or narcotics * impaired renal function (se-creatinine \> 120 μm and/or albuminuria) * uncontrolled hypertension (systolic blood pressure \> 180 mmhg, diastolic blood presure \> 100 mmhg) * any condition that the investigator feels would interfere with trial participation

Keywords: gestational diabetes mellitus incretin glucose homeostasis glp-1 type 2 diabetes mellitus liraglutide victoza